Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 363

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Open access
Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., O’Hare, Thomas·2014·Cancer Cell

Abstract

Summary Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1T315I mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.07.006

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 363

Metadata

Authors
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., Kantarjian, H., Jabbour, E. J., Kornblau, S. M., Lipton, J. H., Rea, D., Stenke, L., Barbany, G., Lange, T., Hernández-Boluda, J.-C., Ossenkoppele, G. J., Press, R. D., Chuah, C., Goldberg, S. L., Wetzler, M., Mahon, F.-X., Etienne, G., Baccarani, M., Soverini, S., Rosti, G., Rousselot, P., Friedman, R., Deininger, M., Reynolds, K. R., Heaton, W. L., Eiring, A. M., Pomicter, A. D., Khorashad, J. S., Kelley, T. W., Baron, R., Druker, B. J., Deininger, M. W., & O’Hare, T.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2014-09
Volume
26
Issue
3
Pages
428-442
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2140351909
Cited by
363
References
47
FWCI
24.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. https://app.cochat.ai/papers/10.1016/j.ccr.2014.07.006
The paper
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., Kantarjian, H., Jabbour, E. J., Kornblau, S. M., Lipton, J. H., Rea, D., Stenke, L., Barbany, G., Lange, T., Hernández-Boluda, J.-C., . . . O’Hare, T. (2014). BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell. https://doi.org/10.1016/j.ccr.2014.07.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.